Printer Friendly

AGOURON PHARMACEUTICALS REPORTS FISCAL 1992 FINANCIAL RESULTS

 AGOURON PHARMACEUTICALS REPORTS FISCAL 1992 FINANCIAL RESULTS
 SAN DIEGO, Aug. 6 /PRNewswire/ -- Agouron Pharmaceuticals Inc. (NASDAQ-NMS: AGPH) reported revenues of $6,847,000 and a net loss of $9,132,000 or $1.47 per share, for its fiscal year ended June 30, 1992 compared to a loss of $6,621,000 or $1.42 per share on revenues of $4,795,000 for the prior year.
 "Agouron's year-end financial results reflect our sustained investment in proprietary research and development," stated Peter Johnson, Agouron's president and chief executive officer. "The return on this investment is increasingly tangible; our promising anti-tumor drug AG-337 will soon enter clinical trials in England; our intravenous anti-cancer drug AG-331 is being readied for clinical evaluation in the United States; plans for a second clinical study of our topical anti-proliferative compound AG-85 are being finalized; our most advanced anti-HIV drug design program is bearing novel, active compounds; and incremental technical progress is being realized in seven other drug discovery programs focused on cancer, viral and inflammatory diseases."
 Agouron Pharmaceuticals Inc. is a pioneer and leader in a new technology for the rational design of novel synthetic drugs based upon the molecular structures of proteins which play key roles in human disease. Agouron is currently applying this technology to the design and development of drugs for treatment of cancer, AIDS and other serious diseases.
 AGOURON PHARMACEUTICALS INC.
 Summary Financial Results Fiscal 1992
 Quarter Ended June 30, Year Ended June 30,
 1992 1991 1992 1991
 Total
 revenues $2,113,000 $1,203,000 $6,847,000 $4,795,000
 Net loss ($2,697,000) ($1,752,000) ($9,132,000) ($6,621,000)
 Net loss per
 share in
 dollars ($0.39) ($0.36) ($1.47) ($1.42)
 Weighted
 average number
 of shares 6,901,000 4,873,000 6,199,000 4,674,000
 -0- 8/6/92
 /CONTACT: Steven S. Cowell, VP and CFO, or Donna Nichols of Agouron Pharmaceuticals, 619-622-3000/
 (AGPH) CO: Agouron Pharmaceuticals Inc. ST: California IN: MTC SU: ERN


LS-AL -- SD001 -- 7732 08/06/92 16:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 6, 1992
Words:344
Previous Article:FBS AND CENTENNIAL TERMINATE ACQUISITION DISCUSSIONS
Next Article:RADA ELECTRONIC INDUSTRIES REPORTS RESULTS
Topics:


Related Articles
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FISCAL 1993 FINANCIAL RESULTS
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FISCAL 1994 FINANCIAL RESULTS
AGOURON PHARMACEUTICALS REPORTS FISCAL 1995 FINANCIAL RESULTS
Agouron Pharmaceuticals Reports Fiscal 1996 Financial Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters